Clinical Significance of the Expression of Bone Morphogenetic Proteins 6 in Different Types of Breast Cancer

丁梅,胡芬,王增辉,杨艳玲,马振玲,李宗富,李润华

DOI: https://doi.org/10.3969/j.issn.1007-9572.2016.11.016

2016-01-01

Abstract:Objective To investigate the expression of bone morphogenetic proteins 6(BMP-6)of different types of breast cancer and its relation with clinical pathological characteristics. Methods From January 2013 to March 2015,we enrolled 426 females patients who were diagnosed with breast cancer by surgery and pathology in the Department of General Surgery of Tangshan Xiehe Hospital. Among these patients,there were 149 Luminal A patients,97 Luminal B patients,72 Her-2 positive patients and 108 Basal-like patients. Real - time fluorescent quantitative PCR was adopted to detect the mRNA expression of BMP-6 of different molecular types,and immunohistochemistry assay was used to detect the protein expression of BMP-6 of different molecular types. Comparison of clinical features among different molecular types of breast cancer patients was made. Results Significant differences were noted in BMP-6 mRNA expression level among different molecular types of cancer tissues(P < 0. 05);BMP-6 mRNA level of Basal-like patients was lower than that of Luminal A patients(P < 0. 05). Different molecular types of cancer tissues all had lower BMP-6 mRNA level than para - cinoma tissues(P < 0. 01). Different molecular types of cancer tissues were significantly different in the protein expression level of BMP-6( χ2 = 19. 01,P = 0. 02);the negative rate( - )of Luminal A type was lower than that of Basal-like type(χ2 = 5. 17,P = 0. 002);the positive( + + + )&nbsp;rate of Luminal A was higher than Basal-like type( χ2 = 8. 84,P < 0. 001). Different molecular types of patients were not significantly different in the lymphatic metastasis rate( P > 0. 05),and were significantly different in tumor size and viscera metastasis rate(P < 0. 01);Basal-like patients had higher viscera metastasis rate than Luminal A patients(χ2 = 14. 71,P <0. 001). Conclusion Differences exist in the expression of BMP-6 among breast cancer tissues of different molecular types,so different BMP-6 treatment regimens can be adopted for different types of breast cancer patients in clinical practice.